CARsgen presents promising CT071 data at EHA annual congress

CARsgen Therapeutics Holdings Limited announced research results on CT071, an autologous CAR T-cell product targeting GPRC5D, for treating newly diagnosed multiple myeloma (NDMM). The data, from an investigator-initiated trial (NCT06407947), was presented at the 30th EHA Annual Congress. CT071, developed using CARsgen's CARcelerate platform, targets GPRC5D for relapsed/refractory multiple myeloma or plasma cell leukemia. An ongoing trial in China (NCT05838131) assesses its safety and efficacy in relapsed/refractory multiple myeloma or plasma cell leukemia. Another trial (NCT06407947) examines its use in NDMM.